Results 91 to 100 of about 49,135 (301)
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. [PDF]
, 2015 Patients at thromboembolic risk with non-valvular atrial fibrillation (AF) can now be managed either with a vitamin K antagonist (VKA) or with a fixed dose of a non-VKA oral anticoagulant (NOAC), while patients with valvular AF have been restricted to ...
De Caterina, R, John Camm, A
core +1 more source
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Blood, 2019 This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to
L. Brandão +17 more
semanticscholar +1 more source
International Journal of Molecular Sciences, 2020 Background: Atherosclerotic plaques are unstable, and their release may result in thrombosis; therefore, currently, antiplatelet therapy with anticoagulants is recommended for the treatment of acute coronary syndrome.
E. Woźniak +3 more
semanticscholar +1 more source
Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani +2 more
wiley +1 more source
Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]
, 2015 Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core +3 more sources
The Discovery of Dabigatran Etexilate [PDF]
Frontiers in Pharmacology, 2013 Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is caused by an excessive stimulation of coagulation. Thrombin is a key serine protease in the coagulation cascade and numerous efforts have been made to develop safe and effective orally active direct thrombin inhibitors (DTIs).
van Ryn, Joanne +6 more
openaire +3 more sources
Journal of Cardiovascular Electrophysiology, EarlyView.ABSTRACT Introduction Obstructive sleep apnea (OSA) is a common risk factor for the development and progression of atrial fibrillation (AF). Whether catheter ablation for AF management in patients with coexisting OSA yields survival benefit remains unclear.
Ghassan Bidaoui +16 more
wiley +1 more source
Patient Preference and Adherence, 2014 Jiyoon C Choi,1 Marco d DiBonaventura,2 Lewis Kopenhafer,2 Winnie W Nelson31LifeScan, Inc, West Chester, PA, 2Health Sciences Practice, Kantar Health, New York, NY, 3Janssen Scientific Affairs LLC, Raritan, NJ, USABackground: Oral dabigatran was recently
Choi JC +3 more
doaj
Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]
, 2018 © 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki +3 more
core +2 more sources
Dabigatran‐induced esophagitis with full circumferential blue pigmentation [PDF]
, 2023 Tomonori Araki +7 more
openalex +1 more source